Evidence map›Paper›PMID 39149169›Full record

ArticleJPGN reports2024

Pediatric eosinophilic gastritis treated with benralizumab: A case report.

Donna Cheung, Dawn Ebach, Benjamin Davis

Abstract readCase Reports
In one paragraph

Article in JPGN reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Donna CheungDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, Pancreatology and Nutrition University of Iowa Iowa City Iowa USA.ORCID https://orcid.org/0000-0003-3976-3243
Dawn EbachDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, Pancreatology and Nutrition University of Iowa Iowa City Iowa USA.
Benjamin DavisDepartment of Internal Medicine, Division of Immunology University of Iowa Iowa City Iowa USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report one of the first cases of eosinophilic gastritis (EoG) in a child under 12 years treated with benralizumab. At 7 years, our patient was started on benralizumab after failing to respond to various combinations of high-dose omeprazole, milk elimination diet, oral viscous budesonide, and oral systemic steroids. He had a complete depletion of gastrointestinal tissue eosinophils with improved symptoms but had symptomatic flares with tapering of background therapy. However, after 4 years on benralizumab he became symptomatic again. Benralizumab may be a viable option for EoG refractory to systemic steroids but only as a short-term adjunct therapy. More robust studies with long-term data are needed, especially in this younger population.

Indexed as

biologicchildreneosinophilstomach

Identifiers

PMID39149169
PMCPMC11322020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.